0
Views
6
CrossRef citations to date
0
Altmetric
Methodology

Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world

, &
Pages 53-60 | Published online: 27 Mar 2012

References

  • Platonov PG Clinical trials in Russia and Eastern Europe: recruitment and quality Int J Clin Pharmacol Ther 2003 41 7 277 280 12875342
  • Tassignon J-P Sinackevich N Speeding the critical path Appl Clin Trials 2004 13 1 42 48
  • Ben-Am M Gemperli B Covelli A Burke G The pharmaceutical industry and oncology in Central and Eastern Europe Ann Oncol. 1999 10 Suppl 6 15 17 10676548
  • Gambrill S Central and Eastern Europe triples global trial participation Centerwatch Monthly 2008 15 8 17
  • The European Parliament and the Council of the European Union Directive 2001/20/EC of the European Parliament and of the Council of April 4, 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use Official Journal of the European Communities 2001 L121 34 44
  • The Commission of the European Communities Commission Directive 2005/28/EC of April 8, 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products Official Journal of the European Union 2005 L91 13 19
  • Capala-Szczurko I Revisiting the European Union Directive in CEE Appl Clin Trials 2006 15 3 56 62
  • Platonov PG Varshavsky S FDA inspections outside the USA: an Eastern European perspective Appl Clin Trials 2004 13 9 60 66
  • Babic D Kucerova I Benchmarking clinical trial practices in Central and Eastern Europe Appl Clin Trials 2003 12 5 56 58
  • Platonov PG Escandon R Varshavsky S Recruitment rates and data quality – are they linked? Appl Clin Trials 2003 12 11 32 34
  • Levinson DR Challenges to FDA’s Ability to Monitor and Inspect Foreign Clinical Trials Washington, DC Department of Health and Human Services, Office of the Inspector General 6 2010 OEI-01-08-00510. Available from: http://oig.hhs.gov/oei/reports/oei-01-08-00510.pdf Accessed January 18, 2012
  • Hirschler B Special Report: Big Pharma’s Global Guinea Pigs. Reuters Business and Financial News, Breaking US and International News [newspaper on the Internet] May 6 2011 Available from: http://www.reuters.com/article/2011/05/06/us-pharmaceuticals-trialsidUSTRE7450SV20110506 Accessed January 18, 2012

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.